Blood-based Biomarker For Parkinson's Disease Market Size, Share & Trends Analysis Report By Biomarker, By Technology, By End Use, By Region, And Segment Forecasts, 2025

List of Tables

Blood-based Biomarker For Parkinson's Disease Market Summary

The global blood-based biomarker for Parkinson's disease market size was estimated at USD 117.79 million in 2024 and is projected to reach USD 350.87 million by 2033, growing at a CAGR of 19.25% from 2025 to 2033. The market is exhibiting significant growth driven by rising prevalence of Parkinson's disease worldwide, increasing investment in neurology diagnostics and biomarker research and advances in proteomics and genomic technologies.

The data from the global burden of disease study 2021, researchers project that by 2050, Parkinson's disease will affect approximately 25.2 million people worldwide across all ages and sexes, an increase of 112% compared to the numbers recorded in 2021. The global incidence of Parkinson's disease (PD) is increasing due to geriatric populations, particularly in North America, Europe, and parts of Asia-Pacific. Parkinson's disease (PD) incidence rates increase significantly with age, particularly among individuals aged 65 and older, making age the primary risk factor for the condition. Some studies consistently show that PD is more prevalent in males than females across all age groups. The rising incidence of PD closely correlates with the expanding aging population worldwide, suggesting that demographic shifts will continue to drive up the number of cases in the coming decades. As life expectancy increases, the burden of Parkinson's disease is expected to grow. The graph below depicts cases of Parkinson's disease in various continents according to the IHME Global Burden of Disease (2024):

This growing patient pool drives urgent demand for early, accurate and minimally invasive diagnostic tools. Blood-based biomarkers offer a promising alternative to traditional clinical and imaging-based diagnosis, which often detects PD only in later stages. As awareness of neurodegenerative diseases increases globally, so does the need for accessible diagnostics, positioning blood-based biomarkers as a critical solution to meet the rising burden of Parkinson's and support earlier therapeutic intervention.

Blood-based Biomarker For Parkinson's Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the blood-based biomarker for Parkinson's disease market report based on technology, biomarker, end use, and region:

Biomarker Outlook (Revenue, USD Million, 2021-2033)
Protein biomarkers
Inflammatory markers
Metabolic markers
Transcriptomic/miRNA
Others
Technology Outlook (Revenue, USD Million, 2021-2033)
ELISA/Immunoassay
Multiplex platforms
NGS/qPCR (genetic)
Mass spectrometry
Others
End Use Outlook (Revenue, USD Million, 2021-2033)
Academic/Research Labs
Pharmaceutical / Biotech (for Clinical Trials)
Hospitals
Clinical Diagnostic Labs
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- India
- China
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Product Code: GVR-4-68040-667-9

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR's Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
1.4. Information/Data Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
- 1.7.1. Commodity flow analysis
- 1.7.2. Global Market: CAGR Calculation
1.8. List of Secondary Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Blood-based Biomarker for Parkinson's Disease Market Variable Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market
- 3.1.2. Ancillary Market
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Rising prevalence of Parkinson's disease worldwide
  - 3.2.1.2. Increasing investment in neurology diagnostics and biomarker research
  - 3.2.1.3. Advances in proteomics and genomic technologies
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. High Costs and Technical Complexity Restrict Accessibility in Low-Resource Settings
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
3.3. Blood-based Biomarker For Parkinson's Disease Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitution
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political & Legal landscape
  - 3.3.2.2. Economic and Social landscape
  - 3.3.2.3. Technological landscape
  - 3.3.2.4. Environmental landscape
- 3.3.3. Regulatory Framework
- 3.3.4. Pricing Analysis
- 3.3.5. Reimbursement Scenario
- 3.3.6. Technological Advancements

Chapter 4. Blood-based Biomarker for Parkinson's Disease Market: Biomarker Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Blood-based Biomarker For Parkinson's Disease Market: Biomarker Movement Analysis
4.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by Biomarker, 2021 to 2033 (USD Million)
4.4. Protein biomarkers
- 4.4.1. Protein biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Inflammatory markers
- 4.5.1. Inflammatory markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Metabolic markers
- 4.6.1. Metabolic markers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Transcriptomic/miRNA
- 4.7.1. Transcriptomic/miRNA Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
- 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Blood-based Biomarker For Parkinson's Disease Market: Animal Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Blood-based Biomarker For Parkinson's Disease Market: Animal type Movement Analysis
5.3. Blood-based Biomarker For Parkinson's Disease Market Size & Trend Analysis, by animal type, 2021 to 2033 (USD Million)
5.4. Dogs
- 5.4.1. Dogs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Cats
- 5.5.1. Cats Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Horses
- 5.6.1. Horses Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
- 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Blood-based Biomarker for Parkinson's Disease Market: Technology Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Blood-based Biomarker for Parkinson's Disease Market: Technology Movement Analysis
6.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
6.4. ELISA/Immunoassay
- 6.4.1. ELISA/Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Multiplex platforms
- 6.5.1. Multiplex platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. NGS/qPCR (genetic)
- 6.6.1. NGS/qPCR (genetic) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Mass spectrometry
- 6.7.1. Mass spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
- 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Blood-based Biomarker for Parkinson's Disease Market: By End Use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Blood-based Biomarker for Parkinson's Disease Market: By End Use Movement Analysis
7.3. Blood-based Biomarker for Parkinson's Disease Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.3.1. Academic/Research Labs
  - 7.3.1.1. Academic/Research Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.2. Pharmaceutical / Biotech
  - 7.3.2.1. Pharmaceutical / Biotech Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.3. Hospitals
  - 7.3.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.4. Clinical Diagnostic Labs
  - 7.3.4.1. Clinical Diagnostic Labs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.3.5. Others
  - 7.3.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Blood-based Biomarker for Parkinson's Disease Market: Regional Estimates & Trend Analysis

8.1. Regional Dashboard
8.2. Blood-based Biomarker for Parkinson's Disease Market Share, By Region, 2024 & 2033 (USD Million)
8.3. Regional Outlook
8.4. North America
- 8.4.1. North America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Regulatory framework/ reimbursement structure
  - 8.4.2.3. Competitive scenario
  - 8.4.2.4. U.S. Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Regulatory framework/ reimbursement structure
  - 8.4.3.3. Competitive scenario
  - 8.4.3.4. Canada Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Regulatory framework/ reimbursement structure
  - 8.4.4.3. Competitive scenario
  - 8.4.4.4. Mexico Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Europe Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Regulatory framework/ reimbursement structure
  - 8.5.2.3. Competitive scenario
  - 8.5.2.4. UK Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Regulatory framework/ reimbursement structure
  - 8.5.3.3. Competitive scenario
  - 8.5.3.4. Germany Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Regulatory framework/ reimbursement structure
  - 8.5.4.3. Competitive scenario
  - 8.5.4.4. France Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Regulatory framework/ reimbursement structure
  - 8.5.5.3. Competitive scenario
  - 8.5.5.4. Italy Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Regulatory framework/ reimbursement structure
  - 8.5.6.3. Competitive scenario
  - 8.5.6.4. Spain Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Regulatory framework/ reimbursement structure
  - 8.5.7.3. Competitive scenario
  - 8.5.7.4. Denmark Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Regulatory framework/ reimbursement structure
  - 8.5.8.3. Competitive scenario
  - 8.5.8.4. Sweden Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Regulatory framework/ reimbursement structure
  - 8.5.9.3. Competitive scenario
  - 8.5.9.4. Norway Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Regulatory framework/ reimbursement structure
  - 8.6.2.3. Competitive scenario
  - 8.6.2.4. Japan Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Regulatory framework/ reimbursement structure
  - 8.6.3.3. Competitive scenario
  - 8.6.3.4. China Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Regulatory framework/ reimbursement structure
  - 8.6.4.3. Competitive scenario
  - 8.6.4.4. India Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Regulatory framework/ reimbursement structure
  - 8.6.5.3. Competitive scenario
  - 8.6.5.4. Australia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Regulatory framework/ reimbursement structure
  - 8.6.6.3. Competitive scenario
  - 8.6.6.4. South Korea Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Regulatory framework/ reimbursement structure
  - 8.6.7.3. Competitive scenario
  - 8.6.7.4. Thailand Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Regulatory framework/ reimbursement structure
  - 8.7.2.3. Competitive scenario
  - 8.7.2.4. Brazil Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Regulatory framework/ reimbursement structure
  - 8.7.3.3. Competitive scenario
  - 8.7.3.4. Argentina Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East & Africa
- 8.8.1. Middle East & Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Regulatory framework/ reimbursement structure
  - 8.8.2.3. Competitive scenario
  - 8.8.2.4. South Africa Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Regulatory framework/ reimbursement structure
  - 8.8.3.3. Competitive scenario
  - 8.8.3.4. Saudi Arabia Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Regulatory framework/ reimbursement structure
  - 8.8.4.3. Competitive scenario
  - 8.8.4.4. UAE Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Regulatory framework/ reimbursement structure
  - 8.8.5.3. Competitive scenario
  - 8.8.5.4. Kuwait Blood-based Biomarker For Parkinson's Disease Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Market Participant Categorization
9.2. Company Market Position Analysis/ Heap Map Analysis
9.3. Company Profiles
- 9.3.1. IDEXX Laboratories, Inc.
  - 9.3.1.1. Participant's Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Product Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. Abbott Laboratories
  - 9.3.2.1. Participant's Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Product Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. ACOBIOM
  - 9.3.3.1. Participant's Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Product Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Alseres Pharmaceuticals
  - 9.3.4.1. Participant's Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Product Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. Banyan Biomarkers
  - 9.3.5.1. Participant's Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Product Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. Bio-Rad Laboratories
  - 9.3.6.1. Participant's Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Product Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. DiaGenic ASA
  - 9.3.7.1. Participant's Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Product Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. Johnson & Johnson
  - 9.3.8.1. Participant's Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Product Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. Merck KGaA
  - 9.3.9.1. Participant's Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Product Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. QIAGEN
  - 9.3.10.1. Participant's Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Product Benchmarking
  - 9.3.10.4. Strategic Initiatives
  - 9.3.10.5. Quanterix
  - 9.3.10.6. Participant's Overview
  - 9.3.10.7. Financial Performance
  - 9.3.10.8. Product Benchmarking
  - 9.3.10.9. Strategic Initiatives
  - 9.3.10.10. Thermo Fisher Scientific
  - 9.3.10.11. Participant's Overview
  - 9.3.10.12. Financial Performance
  - 9.3.10.13. Product Benchmarking
  - 9.3.10.14. Strategic Initiatives
9.4. Strategy Mapping
- 9.4.1. Mergers & Acquisitions
- 9.4.2. Partnerships & Collaborations
- 9.4.3. Product launch
- 9.4.4. Others
9.5. List of other key players